ArticleFrontiers in toxicology2021
Adverse Outcome Pathway Development for Assessment of Lung Carcinogenicity by Nanoparticles.
Article in Frontiers in toxicology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Towards a harmonized testing strategy for nanofibers by integrating toxicological screening and proteomic profiling.Scientific reports · 2025Article
- Long-Term Exposure to Real-Life Polyethylene Terephthalate Nanoplastics Induces Carcinogenesis In Vitro.Environmental science & technology · 2025Article
- Dynamic QSAR modeling for predicting in vivo genotoxicity and inflammation induced by nanoparticles and advanced materials: a time-dose-property/response approach.Journal of nanobiotechnology · 2025Article
- Adverse Outcome Pathways (AOPs) Oriented Approach to Assess In Vitro Hazard of Silica and Lignin Nanomaterials Derived from Biomass Residues.Nanomaterials (Basel, Switzerland) · 2025Article
- Do We Need Titanium Dioxide (TiOToxics · 2025Review
- Pulmonary exposure to renewable diesel exhaust particles alters protein expression and toxicity profiles in bronchoalveolar lavage fluid and plasma of mice.Archives of toxicology · 2025Article
- Comprehensive computational analysis via Adverse Outcome Pathways and Aggregate Exposure Pathways in exploring synergistic effects from radon and tobacco smoke on lung cancer.Frontiers in public health · 2025Article
- Polyethylene Terephthalate Microplastics Generated from Disposable Water Bottles Induce Interferon Signaling Pathways in Mouse Lung Epithelial Cells.Nanomaterials (Basel, Switzerland) · 2024Article
- Why adverse outcome pathways need to be FAIR.ALTEX · 2024Article
- An Adverse Outcome Pathway for food nanomaterial-induced intestinal barrier disruption.Frontiers in toxicology · 2024Article
- Exposure to urban nanoparticles at low PM[Formula: see text] concentrations as a source of oxidative stress and inflammation.Scientific reports · 2023Article
- In Vitro Cell Transformation Assays: A Valuable Approach for Carcinogenic Potentiality Assessment of Nanomaterials.International journal of molecular sciences · 2023Review
- Risk assessment in the 21st century: where are we heading?Toxicology research · 2023Review
- After a Century of Research into Environmental Mutagens and Carcinogens, Where Do We Stand?International journal of environmental research and public health · 2023Review
- Predicting nanomaterials pulmonary toxicity in animals by cell culture models: Achievements and perspectives.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2022Review
- The application of existing genotoxicity methodologies for grouping of nanomaterials: towards an integrated approach to testing and assessment.Particle and fibre toxicology · 2022Article
- Reactive Oxygen Species in the Adverse Outcome Pathway Framework: Toward Creation of Harmonized Consensus Key Events.Frontiers in toxicology · 2022Review
- Particle Safety Assessment in Additive Manufacturing: From Exposure Risks to Advanced Toxicology Testing.Frontiers in toxicology · 2022Review
- FAIRification of nanosafety data to improve applicability of (Q)SAR approaches: A case study onComputational toxicology (Amsterdam, Netherlands) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer, one of the most common and deadly forms of cancer, is in some cases associated with exposure to certain types of particles. With the rise of nanotechnology, there is concern that some engineered nanoparticles may be among such particles. In the absence of epidemiological evidence, assessment of nanoparticle carcinogenicity is currently performed on a time-consuming case-by-case basis, relying mainly on animal experiments. Non-animal alternatives exist, including a few validated cell-based methods accepted for regulatory risk assessment of nanoparticles. Furthermore, new approach methodologies (NAMs), focused on carcinogenic mechanisms and capable of handling the increasing numbers of nanoparticles, have been developed. However, such alternative methods are mainly applied as weight-of-evidence linked to generally required animal data, since challenges remain regarding interpretation of the results. These challenges may be more easily overcome by the novel Adverse Outcome Pathway (AOP) framework, which provides a basis for validation and uptake of alternative mechanism-focused methods in risk assessment. Here, we propose an AOP for lung cancer induced by nanosized foreign matter, anchored to a selection of 18 standardized methods and NAMs for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.